Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4211582
Max Phase: Preclinical
Molecular Formula: C86H99N17O16S3
Molecular Weight: 1723.04
Molecule Type: Unknown
Associated Items:
ID: ALA4211582
Max Phase: Preclinical
Molecular Formula: C86H99N17O16S3
Molecular Weight: 1723.04
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)CCCNC(=S)Nc2ccc(-c3c4ccc(=O)cc-4oc4cc(O)ccc34)c(C(=O)O)c2)CSSCCN(CC(N)=O)C(=O)[C@H](Cc2ccccc2)NC1=O
Standard InChI: InChI=1S/C86H99N17O16S3/c1-49(104)75-82(115)100-68(41-52-21-9-4-10-22-52)83(116)103(47-72(88)107)37-38-121-122-48-69(81(114)98-66(40-51-19-7-3-8-20-51)79(112)99-67(42-53-46-93-62-24-12-11-23-57(53)62)80(113)96-63(77(110)102-75)25-13-14-34-87)101-76(109)64(26-15-35-91-85(89)90)97-78(111)65(39-50-17-5-2-6-18-50)95-73(108)27-16-36-92-86(120)94-54-28-31-58(61(43-54)84(117)118)74-59-32-29-55(105)44-70(59)119-71-45-56(106)30-33-60(71)74/h2-12,17-24,28-33,43-46,49,63-69,75,93,104-105H,13-16,25-27,34-42,47-48,87H2,1H3,(H2,88,107)(H,95,108)(H,96,113)(H,97,111)(H,98,114)(H,99,112)(H,100,115)(H,101,109)(H,102,110)(H,117,118)(H4,89,90,91)(H2,92,94,120)/t49-,63+,64+,65-,66+,67-,68+,69+,75+/m1/s1
Standard InChI Key: QVESYXSSUDWUGO-LHPUUBQNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1723.04 | Molecular Weight (Monoisotopic): 1721.6618 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Ragozin E, Hesin A, Bazylevich A, Tuchinsky H, Bovina A, Shekhter Zahavi T, Oron-Herman M, Kostenich G, Firer MA, Rubinek T, Wolf I, Luboshits G, Sherman MY, Gellerman G.. (2018) New somatostatin-drug conjugates for effective targeting pancreatic cancer., 26 (13): [PMID:30017114] [10.1016/j.bmc.2018.06.032] |
Source(1):